Our results provide evidence of LLLT-dependent reduction of IL-1β, IL-6 and TNFα, and the therapy's ability to inhibit proliferation of inflammatory cells makes it a suitable treatment for synovitis associated with the early stages of OA. This evidence concerns the gene TNF and synovitis.